As early trials show promise, ‘serial biotech entrepreneur’ Steve Gorlin signs on.
latest articles
The controversy revolved around the med-tech company’s 2006 purchase of cardiovascular device maker Guidant.
A look at MN-REACH grant winners can provide some future market insight.
Four of the top 10 highest-rated local health care systems in U.S. are located in the state.
Despite private exchange losses, Minnesota insurer posts strong growth.
There are many credible sites for vetting nonprofits before making charitable contributions.
Does our rank-everything culture make marketing easier or defeat it?
Why do employers need to be wary of provider-sponsored health plans?
Your business’s reputation is gained in inches, but lost in miles.
The startup is reorganizing around smaller, more nimble teams as it continues to grow.
Median sales prices for homes in the metro area reached $242,000 in June — a record that was driven largely by low supply and high demand in the market.
The tile and supplies retailer also released a new design app aimed at bolstering consumer confidence in their purchases.
Med-tech veteran takes helm, while reason for John Schellhorn's exit from the private med-tech company remain unclear.
The drug company will use the money to conduct clinical trials to prove the effectiveness of its flagship product, DM199.
But the company thinks the space will be too small by next year.
Stock replaces former CEO Madhu Vuppuluri, who has been repositioned within the capital management division of Essar Steel Minnesota’s parent company.